Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 8/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | CDC25B | P30305 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429128 | 0.87 | ADK (0.44) | ADKBCHESLC29A1HTR1APDE2A | |
| SCHEMBL14428969 | 0.87 | BCHE (0.48) | BCHEHTR1APDE2AHSPA5PTPN1 | |
| SCHEMBL14429059 | 0.83 | TYMP (0.57) | BCHESLC29A1HTR1APDE2ATP53 | |
| SCHEMBL14429138 | 0.83 | BCHE (0.40) | ADKBCHEHTR1APDE2APTPN1 | |
| SCHEMBL25353749 | 0.80 | HTR1A (0.47) | ADKBCHESLC29A1HTR1APDE2A | |
| SCHEMBL25353313 | 0.78 | PDE2A (0.57) | ADKBCHEHTR1APDE2AHSPA5 | |
| SCHEMBL23989128 | 0.78 | PDE2A (0.57) | ADKBCHEHTR1APDE2AHSPA5 | |
| SCHEMBL6738697 | 0.78 | BCHE (0.51) | BCHEHTR1APDE2APTPN1CDC25B | |
| SCHEMBL23989127 | 0.78 | PDE2A (0.57) | ADKBCHEHTR1APDE2AHSPA5 | |
| SCHEMBL1738235 | 0.78 | BCHE (0.51) | BCHEHTR1APDE2APTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | ADK 359/4885BCHE 3255/4885SLC29A1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.